標(biāo)題: Titlebook: Biomedical Aspects of Drug Targeting; Vladimir Muzykantov,Vladimir Torchilin Book 2002 Springer Science+Business Media New York 2002 Epoxi [打印本頁(yè)] 作者: probiotic 時(shí)間: 2025-3-21 17:18
書目名稱Biomedical Aspects of Drug Targeting影響因子(影響力)
書目名稱Biomedical Aspects of Drug Targeting影響因子(影響力)學(xué)科排名
書目名稱Biomedical Aspects of Drug Targeting網(wǎng)絡(luò)公開度
書目名稱Biomedical Aspects of Drug Targeting網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomedical Aspects of Drug Targeting被引頻次
書目名稱Biomedical Aspects of Drug Targeting被引頻次學(xué)科排名
書目名稱Biomedical Aspects of Drug Targeting年度引用
書目名稱Biomedical Aspects of Drug Targeting年度引用學(xué)科排名
書目名稱Biomedical Aspects of Drug Targeting讀者反饋
書目名稱Biomedical Aspects of Drug Targeting讀者反饋學(xué)科排名
作者: 不可思議 時(shí)間: 2025-3-21 20:35
attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a ser978-1-4419-5312-4978-1-4757-4627-3作者: 泥沼 時(shí)間: 2025-3-22 02:22 作者: Respond 時(shí)間: 2025-3-22 08:33 作者: Organization 時(shí)間: 2025-3-22 08:59
Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Cavthe ability of many monoclonal antibodies to reach their cell-specific antigens and thus to achieve effective tissue- or cell-directed pharmaco-delivery in vivo (1–3). Understanding general and selective transport across key cell barriers to pharmaco-delivery in vivo is fundamental to achieving effe作者: 手術(shù)刀 時(shí)間: 2025-3-22 15:54 作者: analogous 時(shí)間: 2025-3-22 17:25 作者: fledged 時(shí)間: 2025-3-22 23:25
Regel-orientierte Programmierungulation or hyperactivity intravascularly, neoexpression or hyperexpression of various vascular adhesion molecules, or the metabolites that may be incorporated into the cellular components of the atherosclerotic lesions may provide novel and specific diagnostic and therapeutic applications.作者: 夸張 時(shí)間: 2025-3-23 01:53
Rüdiger Esser,Elisabeth Feldmarthe ability of many monoclonal antibodies to reach their cell-specific antigens and thus to achieve effective tissue- or cell-directed pharmaco-delivery in vivo (1–3). Understanding general and selective transport across key cell barriers to pharmaco-delivery in vivo is fundamental to achieving effe作者: 眨眼 時(shí)間: 2025-3-23 08:37
Sheng Qu,Xianliang Shi,Guowei Huaomponent has largely been ignored. Calculations of tumor cell loss have revealed that, in contrast to normal tissues, 30–80% of the progeny of tumor cell divisions shortly undergo degeneration. In tumors, the imperfect vasculature and impaired phagocytic response permit the accumulation of degenerat作者: collagenase 時(shí)間: 2025-3-23 10:41
Book 2002ncy and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To作者: PAGAN 時(shí)間: 2025-3-23 15:25
https://doi.org/10.1007/978-3-642-71455-9the heart. This chapter will focus primarily on targeting the oncotic myocardium. Targeting the apoptotic myocardium will not be considered in detail, but an introduction to the latest advances will be provided.作者: 補(bǔ)助 時(shí)間: 2025-3-23 21:42 作者: 磨坊 時(shí)間: 2025-3-24 01:59
https://doi.org/10.1007/978-3-322-81190-5unique EPR effect for tumor-targeted delivery of drugs. Thus, polymeric drugs and microparticles, including micellar compounds or liposomes, can be delivered with greater selectivity to tumors because of the EPR effect.作者: 不可磨滅 時(shí)間: 2025-3-24 05:25 作者: Mendacious 時(shí)間: 2025-3-24 07:08 作者: 殺菌劑 時(shí)間: 2025-3-24 14:42 作者: mutineer 時(shí)間: 2025-3-24 18:49
Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumorunique EPR effect for tumor-targeted delivery of drugs. Thus, polymeric drugs and microparticles, including micellar compounds or liposomes, can be delivered with greater selectivity to tumors because of the EPR effect.作者: Insufficient 時(shí)間: 2025-3-24 21:04
Ligand-Directed Destruction of Tumor Vasculatureutant endothelial cells lacking the target antigen is unlikely because they comprise a normal, genetically stable cell population. Finally, since tumor vessels share common morphological and biochemical properties, this strategy should be applicable to different tumor types.作者: ARIA 時(shí)間: 2025-3-25 01:32 作者: inventory 時(shí)間: 2025-3-25 04:56
Polymer-Drug Conjugates: Targeting Cancere properties of natural or synthetic water soluble polymers to provide opportunities for improved chemotherapy. They include biologically active polymeric drugs, polymer-drug conjugates, block copolymer micelles, polymer-protein conjugates and polymer-based non-viral vectors are currently being designed for gene delivery.作者: antenna 時(shí)間: 2025-3-25 09:04 作者: 冰雹 時(shí)間: 2025-3-25 13:31 作者: contrast-medium 時(shí)間: 2025-3-25 16:18
LISP Functions for Powerful Programming,d therapies for a variety of acquired diseases. In essence, the approach involves the delivery of nucleic acids (i.e. genes) into cells whereupon the host cell’s machinery will be used for transcription and translation, leading to . production of a protein which in turn will have an impact on cell function.作者: Toxoid-Vaccines 時(shí)間: 2025-3-25 21:14
Yacan Wang,Tao Lu,Chunhui Zhangth and signaling pathways, predominantly within the cancer cell. Antigens aberrantly expressed on the cancer cell surface also afford possible valid molecular targets. Thus antibodies against tumor related antigens are a class of drugs that fit the new paradigm for cancer drug development and treatment.作者: 使顯得不重要 時(shí)間: 2025-3-26 03:40
Biological Barriers for Drug Targetingsing of a drug, metabolization of carriers, etc), technological (e.g., associated with production, dosing, shelf-life of a drug-carrier complexes) and socioeconomical (e.g., price, practical utility and public accessibility of a targeting strategy).作者: projectile 時(shí)間: 2025-3-26 08:15
Intravascular Re-Targeting of Viral Vectorsd therapies for a variety of acquired diseases. In essence, the approach involves the delivery of nucleic acids (i.e. genes) into cells whereupon the host cell’s machinery will be used for transcription and translation, leading to . production of a protein which in turn will have an impact on cell function.作者: 人工制品 時(shí)間: 2025-3-26 09:51 作者: strain 時(shí)間: 2025-3-26 15:26
More on Navigating the Lisp Machine,ered to the pulmonary endothelium. Effective, safe and specific delivery of drugs, enzymes and genetic materials to this target may help to improve current modalities in therapies and prophylaxis of pulmonary hypertension, oxidative stress, embolism, edema, acute lung injury, and other disease conditions.作者: 符合國(guó)情 時(shí)間: 2025-3-26 18:06
https://doi.org/10.1007/978-3-322-81190-5e properties of natural or synthetic water soluble polymers to provide opportunities for improved chemotherapy. They include biologically active polymeric drugs, polymer-drug conjugates, block copolymer micelles, polymer-protein conjugates and polymer-based non-viral vectors are currently being designed for gene delivery.作者: fructose 時(shí)間: 2025-3-27 00:14
Strategies and Means for Drug Targeting: An Overviewcal processes or with defective biological pathways, but not on its selective accumulation in the specific intracellular compartment or in the target cell, organ or tissue. Traditional pharmaceutical agents, practically independent of the administration route, distribute evenly (or at least proporti作者: 疼死我了 時(shí)間: 2025-3-27 02:05 作者: 燦爛 時(shí)間: 2025-3-27 08:51 作者: Coma704 時(shí)間: 2025-3-27 10:09
Targeting Atherosclerotic Plaquesvascular ultrasound (3) can demonstrate the precise location of the lesions, the extent of luminal narrowing and plaque thickening. However, both methods are invasive and cannot provide the composition or the metabolic status of the atherosclerotic lesion (4). Plaques rich in macrophages and foam ce作者: 音樂(lè)學(xué)者 時(shí)間: 2025-3-27 17:30
Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Cavssays that screen for pharmacological actions on the cell type of interest are frequently used in the design of new drugs. Although the potential for such agents is great and certainly justified by their success in vitro, they frequently perform much less effectively in vivo where the agent must rea作者: Judicious 時(shí)間: 2025-3-27 20:40 作者: 笨拙的我 時(shí)間: 2025-3-28 00:44 作者: 聚集 時(shí)間: 2025-3-28 02:23
Intravascular Re-Targeting of Viral Vectorstially envisaged as a strategy to correct inherited genetic disorders, the approach has been substantially broadened to encompass the use of gene-based therapies for a variety of acquired diseases. In essence, the approach involves the delivery of nucleic acids (i.e. genes) into cells whereupon the 作者: CREEK 時(shí)間: 2025-3-28 06:41 作者: arbiter 時(shí)間: 2025-3-28 11:54 作者: Nefarious 時(shí)間: 2025-3-28 17:27 作者: generic 時(shí)間: 2025-3-28 20:54
Tumor Necrosis Treatment and Imaging of Solid Tumorsed in our laboratory. Tumor Necrosis Therapy (TNT) represents a radical departure from current methods that employ monoclonal antibodies (MAbs) to bind to tumor-associated cell surface antigens and require the use of different antibodies for each type of tumor. In contrast, TNT is based upon the hyp作者: 服從 時(shí)間: 2025-3-29 00:16
Targeted Apoptosis: Antibodies Linked to RNA Damaging Agentswhich new drugs can be designed. For small molecule drugs, the focus is on interfering with molecular targets that contribute to deregulated cell growth and signaling pathways, predominantly within the cancer cell. Antigens aberrantly expressed on the cancer cell surface also afford possible valid m作者: 細(xì)微差別 時(shí)間: 2025-3-29 03:30 作者: Frequency 時(shí)間: 2025-3-29 08:06
Rüdiger Esser,Elisabeth FeldmarLarge-scale studies with mortality endpoints comparing fibrinolytic therapy with placebo in patients with acute myocardial infarction (AMI) have documented the benefit of timely dissolution of coronary arterial thrombi by intravenous infusion of plasminogen activators (Fig. 1).(1)作者: 殘忍 時(shí)間: 2025-3-29 13:45 作者: certain 時(shí)間: 2025-3-29 18:48
Thrombus Targeting of Plasminogen Activators and AnticoagulantsLarge-scale studies with mortality endpoints comparing fibrinolytic therapy with placebo in patients with acute myocardial infarction (AMI) have documented the benefit of timely dissolution of coronary arterial thrombi by intravenous infusion of plasminogen activators (Fig. 1).(1)作者: Semblance 時(shí)間: 2025-3-29 21:34 作者: Flustered 時(shí)間: 2025-3-30 02:14 作者: 標(biāo)準(zhǔn) 時(shí)間: 2025-3-30 05:37
The Most Interesting City in Austriaormidable challenges. Drug targeting strategies have to traverse diverse barriers: biological (e.g., associated with drug delivery, subcellular addressing of a drug, metabolization of carriers, etc), technological (e.g., associated with production, dosing, shelf-life of a drug-carrier complexes) and作者: 難取悅 時(shí)間: 2025-3-30 11:19
https://doi.org/10.1007/978-3-642-71455-9ns. Since the heart is an end-differentiated organ that has no substantial regenerative properties, any injury to the heart could potentially lead to high morbidity and mortality. The causes of myocardial injury are varied. Acute myocardial infarction results in oncotic myocardial cell death, wherea作者: 恃強(qiáng)凌弱 時(shí)間: 2025-3-30 15:38 作者: 兵團(tuán) 時(shí)間: 2025-3-30 18:18 作者: MUMP 時(shí)間: 2025-3-31 00:21
More on Navigating the Lisp Machine,al cells in the lung blood vessels are vulnerable to oxidative, thrombotic and inflammatory insults and represent an important target for therapies. However, despite the huge surface and high accessibility of this target to blood, only a minor fraction of circulating therapeutics is adequately deliv作者: Hormones 時(shí)間: 2025-3-31 04:05
https://doi.org/10.1007/978-1-4613-1991-7vehicles must be considered. The current technology for detecting sites of inflammation uses isolated, radiolabeled neutrophils and gamma imaging (1). This method is cumbersome because it requires obtaining blood from the patient to isolate and short-term culture neutrophil, radiolabeling (usually w作者: motivate 時(shí)間: 2025-3-31 06:30
LISP Functions for Powerful Programming,tially envisaged as a strategy to correct inherited genetic disorders, the approach has been substantially broadened to encompass the use of gene-based therapies for a variety of acquired diseases. In essence, the approach involves the delivery of nucleic acids (i.e. genes) into cells whereupon the
